Diabetes & Metabolism Journal

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus

Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K.Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Seung Kim, Sei Hyun Baik

Diabetes Metab J. 2021;45(4):606-612. Published online September 9, 2020
DOI: https://doi.org/10.4093/dmj.2020.0047

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus

Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K.Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Esong Kim, Sei Hyun Baik

Diabetes & Metabolism Journal. 2021;45(4):606-612

Link1

Link2 Link3

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes

S. J. Yang, K. W. Min, S. K. Gupta, J. Y. Park, V. K. Shivane, S. U. Pitale, P. K. Agarwal, A. Sosale, P. Gandhi, M. Dharmalingam, V. Mohan, U. Mahesh, D. M. Kim, Y. S. Kim, J. A. Kim, P. K. Kim, S. H. Baik

Diabetes, Obesity and Metabolism. 2012;15(5):410-416

Link1 Link2

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes ( TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial

Julie Dubourg, Pascale Fouqueray, Damien Quinslot, Jean‐Marie Grouin, Kohei Kaku

Diabetes, Obesity and Metabolism. 2021;24(4):609-619

Link1 Link2 Link3

A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone

Chan-Hee Jung, Eun-Jung Rhee, Won-Young Lee, Kyung Wan Min, Vyankatesh K. Shivane, Aravind R. Sosale, Hak Chul Jang, Choon Hee Chung, Il Seong Nam-Goong,

Diabetes, Obesity and Metabolism. 2018;20(6):1535-1541

Link1 Link2

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study

Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima

Journal of Diabetes Investigation. 2020;11(3):662-671

Link1 Link2 Link3

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)

Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku

Diabetes, Obesity and Metabolism. 2018;20(5):1176-1185

Link1 Link2 Link3 Link4

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study

Yutaka Seino, Yasuo Terauchi, Xiangling Wang, Daisuke Watanabe, Elisabeth Niemoeller,

Journal of Diabetes Investigation. 2017;9(1):108-118

Link1 Link2

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL

Marina Vladimirovna Shestakova

Diabetes mellitus. 2011;14(4):75-80

Link1 Link2

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, Seitaro Asahina, Taishi Sakatani

Diabetology International. 2018;10(1):37-50

Link1 Link2

Link3

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

T. Kadowaki, K. Kondo

Diabetes, Obesity and Metabolism. 2013;16(5):418-425

Link1 Link2